NewsRoom Articles - Page 2 of 224

FridayJan 16, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease

Behçet’s disease is characterized by unpredictable flare-ups and periods of remission, making long-term management particularly challenging. Current treatment strategies for the disease focus on controlling inflammation and suppressing immune activity using corticosteroids, immunosuppressants and biologic agents. Soligenix has released positive top-line results from its phase 2 clinical trial evaluating SGX945 for the treatment of aphthous ulcers associated with Behçet’s. Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that significantly affect quality of life. Because available treatments are limited and often inconsistent, clinical trial updates in this disease area carry…

FridayJan 16, 2026 10:00 am

Experts are Astounded by the Vaccine Policy Change in the US

The recent vaccine policy changes that the U.S. government announced have astounded experts because the changes reduce recommended vaccines by one third and put the U.S. behinds its peer countries. This change shifts the U.S. from the position of leader on vaccination to a country that lags other developed nations on matters of disease prevention. This policy change marks the latest escalation of the HHS secretary, John F. Kennedy Jr., who has for long been a skeptic of vaccines and is now in a position where he can make policy decisions that affect the entire country. Daniel Jernigan, the National Center for Emerging Zoonotic Infectious Diseases’ former director,…

ThursdayJan 15, 2026 9:00 am

Michigan State University Research Says Suppressing Postoperative Pain Could Delay Healing

The normal practice after someone has undergone a surgical procedure has been to administer anti-inflammatory medications. However, new research conducted at Michigan State University (MSU) suggests that this could be counterproductive and may be the reason why some patients develop chronic pain that lasts for years after their surgery. The study found that allowing inflammation to happen naturally expedited the recovery process after injury or surgery and that pain ceased a lot faster if inflammation wasn’t blocked. Associate Professor Geoffroy Laumet, the senior author of the study, explains that the research team was surprised when they found that blocking inflammation…

WednesdayJan 14, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances Solutions for Hard-to-Diagnose CTCL

CTCL is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages. Delayed diagnosis has meaningful clinical consequences. Within this challenging diagnostic and treatment landscape, Soligenix is advancing a novel therapeutic approach for CTCL through its development of HyBryte(TM). Cutaneous T-cell lymphoma, or CTCL, is a rare form of non-Hodgkin lymphoma that primarily affects the skin, often presenting with symptoms that closely resemble common dermatologic conditions such as eczema or psoriasis, leading to frequent misdiagnosis and delayed treatment. These diagnostic delays can allow the disease to progress silently for years, increasing patient suffering…

TuesdayJan 13, 2026 10:00 am

Penn State to Participate in Researching Potential Treatment for Pediatric Brain Cancer

A new collaboration between Penn State College of Medicine and Targepeutics seeks to advance research into a promising combination therapy that offers hope to families with children diagnosed with DIPG (diffuse intrinsic pontine glioma). This glioma is devastating and currently has limited therapy options. Patients diagnosed with this cancer survive for less than a year on average. A new combo therapy involving an immunotoxin dubbed GB13 and radiotherapy has shown promise in preclinical trials where approaches like chemotherapy or targeted therapy have had dismal results. The collaboration seeks to advance this treatment to clinical studies and eventual approval by the FDA. The planned clinical trial seeks to recruit pediatric participants, a reflection of how…

FridayJan 09, 2026 10:00 am

New ‘Nanozigzag’ Biomaterial Shows Potential in Revolutionizing Cancer Immunotherapy

Immunotherapy has emerged as a more gentle way to treat cancer over the past few years. However, it is very expensive and results are usually inconsistent among patients, especially those suffering from solid tumors. Researchers in Hong Kong have come up with a biomaterial containing silica that can help to address the current shortcomings of immunotherapy and dramatically improve efficacy rates. Prof. Yung Kin-lam, who led the team of researchers, explains that the nanomaterial they developed is biocompatible, non-toxic, natural and comes in the shape of a nanomatrix. This biomaterial accelerates the maturation of dendritic cells (DCs) outside the body of the patient and these are infused into the patient to wake up the body’s ability…

ThursdayJan 08, 2026 10:00 am

Analysis Finds 40 Million Individuals Seek Health Care Advice from ChatGPT

At least 40 million individuals from around the world use ChatGPT each day seeking information on health care-related topics, an analysis conducted by AI tool Knit. The report underscores how people use the technology and the need for oversight so that millions don’t get wrong information on such an important matter as their health. The report shows that patients view the AI chatbot ChatGPT like an ally as they navigate health care-related issues they are facing. The uses for which people seek out help from the chatbot include getting help interpreting medical bills, identifying any overcharges in those bills, how to appeal an insurance claim denial or even self-diagnosis in situations when a health care…

WednesdayJan 07, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’

LIXTE is advancing a first-in-class PP2A inhibitor platform designed to enhance, rather than replace, established chemotherapy and immunotherapy regimens. The company is conducting multiple active clinical trials in solid tumors with significant unmet medical need, supported by academic and industry collaborations. LIXTE’s scientific strategy is protected by a comprehensive patent portfolio, with management noting no known direct competitors targeting PP2A inhibition. Strategic actions in 2025, including the acquisition of Liora Technologies and a registered direct offering completed in December 2025, reflect an effort to broaden capabilities and strengthen operational flexibility. Expansion of the ovarian clear cell carcinoma trial in December…

MondayJan 05, 2026 10:00 am

The WHO Highlights Successes, Challenges to Global Health

The World Health Organization (WHO), the agency of the United Nations responsible for overseeing matters related to global health, revealed that 2025 was marked by notable progress in ensuring populations around the world were supported to have good health. However, climate shocks, conflicts and funding cuts strained many health systems around the world and put a damper on the prospects for sustained improvements to health in the years to come. Regarding disease control, the health body highlighted notable successes that were registered. For example, it pointed out a number of countries that hit historic milestones in the elimination of infectious diseases. Brazil stood out as…

MondayDec 29, 2025 10:00 am

Experts’ Views on Screen Time and Lifestyle on Pediatric Brain Tumors

The young population faces an increasing health challenge posed by brain tumors affecting adolescents and children. While their occurrence isn’t as common as that of other cancers in this demographic group, brain cancers account for the biggest fraction of fatalities related to cancer in this group. Many questions have therefore emerged regarding whether modern screens and lifestyles play a role in the rise of brain cancer among younger people. The general consensus within the scientific community is that there is no rigorous evidence suggesting that extensive time on screens or the use of mobile phones plays a causative role in the growing cases of brain tumors among adolescents…